GPIIbIIIa inhibitors as adjunctive therapy in acute myocardial infarction

International Journal of Cardiology

Volumn 69, Issue 3, 1999, Pages 231-236

  Salame, Mahomed ^a   Verheye, Stefan ^a   More, Ranjit ^b   King III, Spencer B ^a   Chronos, Nicolas ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Acute myocardial infarction; Angioplasty; Antiplatelet; GPIIbIIIa; Thrombolysis

Indexed keywords

ABCIXIMAB; ALTEPLASE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; STREPTOKINASE;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANGIOPLASTY; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

EID: 0033152575     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(99)00046-7     Document Type: Note

References (22)

1. Fuster V. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 326:(4):1992;242-250.
2. The effect of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Eng J Med. 329:1993;1615-1622.
3. Simes R.J., Topol E.J., Holmes D.R., et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation. 91:1995;1923-1928.
4. Ellis S.G., Topol E.J., George B.S., et al. Recurrent ischemia without warning. Analysis of risk factors for in-hospital ischemic events following successful thrombolysis with intravenous tissue plasminogen activator. Circulation. 80:1989;1159-1165.
5. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 2:1988;349-360.
6. Kleiman N.S., Ohman E.M., Califf R.M., et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol. 22:1993;381-389.
7. Combining thrombolysis with platelet glycoprotein IIbIIIa inhibitor lamifiban. Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM Trial. J Am Coll Cardiol. 32:1998;2003-2010.
8. Ohman E.M., Kleiman N.S., Gacioch G., et al. Combined accelerated tissue plasminogen activator and platelet GPIIbIIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomised placebo-controlled, dose-ranging trial. Circulation. 95:1997;846-854.
9. Miller J.M., Ohman E.M., Schildcrout J.S., et al. Survival benefit of abciximab administration during early rescue angioplasty. Analysis of 387 patients from GUSTO-III trial. J Am Coll Cardiol. 31:(Suppl A):1998;191A.
10. Brodie B.R., Grines C.L., Ivanhoe R., et al. Six month clinical and angiographic follow-up after direct angioplasty for acute myocardial infarction. Circulation. 25:1994;156-162.
11. Lefkovits J., Ivanhoe R., Califf R., et al. Effects of platelet glycoprotein IIbIIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on the acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol. 77:1996;1045-1051.
12. Brener S.J., Barr L.A., Burchenal J.E.B., et al. Randomised, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 98:1998;734-741.
13. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet. 349:1997;1422-1428.
14. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
15. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
16. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
17. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
18. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 349:1997;1429-1435.
19. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 96:1997;1445-1453.
20. Weaver W.D., Simes R.J., Betrieu A., Grines C.L., Zijlstra F., Garcia E., Grinfeld L., Gibbons R.J., Ribeiro E.E., DeWood M.A., Ribichini F. Primary coronary angioplasty vs. intravenous thrombolysis for treatment of acute myocardial infarction: a quantitative overview of their comparative effectiveness. J Am Med Assoc. 278:1997;2093-2098.
21. Antman E.M., Guigliano R.P., McCabe C.H., et al. Abciximab (ReoPro) potentiates thrombolysis in S.T. segment elevation myocardial infarction. Results of TIMI14 trial. J Am Coll Cardiol. 31:(Suppl A):1998;191A.
22. Ohman E.M., Lincoff A.M., Bode C., et al. Enhanced early reperfusion at 60 minutes with low dose reteplase combined with full dose abciximab in acute myocardial infarction: Preliminary results from the GUSTO-4 pilot (Speed) dose-ranging trial. Circulation. 98:(Suppl I):1998;504.